Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.
Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.
Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.
Drs Thomas Hutson and Scott Tykodi explain when to consider a debulking surgery for patients with renal cell carcinoma.
Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.
Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.
The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.
Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.